Gapping up
In reaction to strong earnings/guidance:
- CONN +13.1%, AFYA +1.4%
Select metals/mining stocks trading higher:
- EGO +5.8%, DRD +4.9%, AG +2.2%, KGC +1%, SLV +1%, AUY +0.6%, GDX +0.6%, NEM +0.5%
Other news:
- MDCO +14.4% (presents First Phase 3 Trial results of Inclisiran; achieved 54% LDL-C lowering)
- MAMS +12.3% (agrees to be acquired by Kerridge Commercial Systems for $12.12/share in cash)
- CXO +3.9% (to sell its assets in the New Mexico Shelf to an affiliate of Spur Energy Partners LLC for $925 million; additionally, Board authorizes $1.5 bln common stock repurchase plan)
- CRSP +3.2% (enters into $200 mln market sale agreement with Jefferies)
- OBSV +2.2% (reports results from mechanism of action trial of its oral oxytocin receptor antagonist, nolasiban)
- KURA +1.3% (announces 'positive' results from an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory urothelial carcinomas that carry HRAS mutations)
Analyst comments:
- GERN +5% (initiated with a Buy at H.C. Wainwright; tgt $4)
- SNAP +1.6% (upgraded to Outperform from In-line at Evercore ISI)
- SQ +1% (upgraded to Buy from Hold at SunTrust)